<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508258</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-664</org_study_id>
    <nct_id>NCT03508258</nct_id>
  </id_info>
  <brief_title>Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)</brief_title>
  <official_title>Investigating the Association of Type of Anticoagulation Treatment for Non-valvular Atrial Fibrillation and Risk of Bleeding in England</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of patients with nonvalvular atrial fibrillation (NVAF) who are newly prescribed NOACs
      (Novel Oral Anticoagulants) in routine clinical practice in England
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">December 28, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of major bleeding</measure>
    <time_frame>At the end of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of intracranial bleeding</measure>
    <time_frame>At the end of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of gastrointestinal bleeding</measure>
    <time_frame>At the end of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically relevant non-major bleeding</measure>
    <time_frame>At the end of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of ischemic stroke</measure>
    <time_frame>At the end of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of unspecified stroke</measure>
    <time_frame>At the end of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of systemic embolic events</measure>
    <time_frame>At the end of 1 year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">10000</enrollment>
  <condition>Non-valvular Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Participants with NVAF starting Apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with NVAF starting Warfarin</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional</intervention_name>
    <description>Non-interventional</description>
    <arm_group_label>Participants with NVAF starting Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>Participants with NVAF starting Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        NVAF patients newly prescribed NOACs in England
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of atrial fibrillation at or prior to index (the initiation of treatment)

          -  Incident prescription of an oral anticoagulant (index date)

          -  Patients with at least one year of computerized data prior to index date

        Exclusion Criteria:

          -  Patients identified with a diagnosis of mechanical heart valve replacement or mitral
             stenosis identified at any point in the pre-index period in either CPRD by Read codes
             or in HES as ICD-10/OPCS codes

          -  Patients with indication of venous thromboembolism (pulmonary embolism or deep vein
             thrombosis) identified in in either CPRD by Read codes or HES by ICD-10/OPCS codes
             within 3 months prior to index

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

